Extranodal Natural Killer T-cell Lymphoma

• CLINICAL_TRIALS trial_result · 2025-03-13
  Clinical Trial Update: Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma [Phase 1]

  This clinical trial update reports a Phase 1 study evaluating the combination of sintilimab and linperlisib for relapsed or refractory extra…

• CLINICAL_TRIALS trial_result · 2024-06-18
  Clinical Trial Update: A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) [Phase 2]

  A Phase 2 study of CS1001 in relapsed or refractory Extranodal Natural Killer/T-Cell Lymphoma has completed enrollment with results posted o…

• CLINICAL_TRIALS trial_result · 2024-02-13
  Clinical Trial Update: The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma [Phase 3]

  Phase 3 trial comparing chidamide plus anti-PD-1 antibody and peg-aspargase versus DDGP in newly diagnosed stage III-IV extranodal natural k…